Pulmonary Cell News Volume 8.38 | Oct 3 2019

TOP STORY

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with non-small-cell lung cancer, independent of the programmed death ligand 1 expression level. [N Engl J Med] Abstract

(Ranked by impact factor of the journal)

In Vivo Clearance of Nanoparticles by Transcytosis across Alveolar Epithelial Cells

Scientists describe a novel, highly effective pathway for the particles to cross the alveolar epithelium and reach the lymph and bloodstream. [PLoS One] Full Article

Allyl Isothiocyanate May Reverse the Expression of MRP1 in COPD Rats via the Notch1 Signaling Pathway

The roles of AITC in up-regulating the MRP1 expression and its relationship with the activation of the Notch1 signaling pathway were investigated by combining the in vivo and in vitro experiments. [Arch Pharm Res] Abstract

LUNG CANCER

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers

The authors demonstrated that knockout, suppression, or degradation of SHOC2, a positive regulator of mitogen-activated protein kinase signaling, specifically cooperated with MEK inhibition to impair proliferation in RAS-driven cancer cells. [Cell Rep] Full Article | Graphical Abstract

Cell Membrane Based Biomimetic Nanocomposites for Targeted Therapy of Drug Resistant EGFR-Mutated Lung Cancer

Scientists developed a biomimetic nano-carrier to enhance the chemo-therapeutic efficacy of doxorubicin and icotinib in a chemo-resistant non-small cell lung cancer cell line harboring a mutation in the epidermal growth factor receptor (EGFR). [Nanoscale] Abstract | Graphical Abstract

Mst1/2 Kinases Restrain Transformation in a Novel Transgenic Model of Ras Driven Non-Small Cell Lung Cancer

Researchers revealed that loss of Mst1/2 promoted aggressive lung adenocarcinoma and large-scale proteomic analysis revealed upregulation of PKM2 in the lungs of mice with genetic deletion of Mst1/2. [Oncogene] Abstract

CNOT2 Is Critically Involved in Atorvastatin Induced Apoptotic and Autophagic Cell Death in Non-Small Cell Lung Cancers

Overexpression of CCR4-NOT transcription complex subunit 2 (CNOT2) weakly reversed the ability of atorvastatin to increase cytotoxicity, sub G1 population, cleavages of polymerase and caspase 3, light chain 3II conversion and p62/p62/sequestosome 1 accumulation in H1299 cells. [Cancers] Full Article

Long Noncoding RNA LINC00657 Induced by SP1 Contributes to the Non-Small Cell Lung Cancer Progression through Targeting miR-26b-5p/COMMD8 Axis

Quantitative reverse-transcription polymerase chain reaction revealed that LINC00657 level was apparently elevated in non-small-cell lung cancer (NSCLC) cells. Loss-of function assays demonstrated that LINC00657 silence retarded cell proliferation and migration in NSCLC cells. [J Cell Physiol] Abstract

Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922

A combined approach consisting of HSF-1 knockdown and low concentrations of the heat shock protein 90 (Hsp90) inhibitor NVP-AUY922 reduced the Hsp90 client protein Akt and potentiated radiosensitization, which involved an impaired homologous recombination mediated by Rad51. [Cells] Full Article

Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News.

“NRF2 Addiction” in Lung Cancer Cells and Its Impact on Cancer Therapy

Nuclear factor erythroid 2-like factor 2 (NRF2) activation influences many of the hallmarks of cancer and their signaling pathways, mainly apoptosis, proliferation, angiogenesis, metastasis, and metabolic reprogramming to establish cellular metabolic processes leading to “NRF2 addiction” in lung cancer cells. [Cancer Lett] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Genentech’s Tecentriq (Atezolizumab) Improves Overall Survival as a First-Line Monotherapy in Certain People with Advanced Non-Small Cell Lung Cancer

Genentech announced positive data from the Phase III IMpower110 study evaluating Tecentriq^® as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations. [Genentech] Press Release

Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (Nivolumab) Plus Low-Dose Yervoy (Ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company announced results from Part 1 of the Phase III CheckMate -227 trial evaluating Opdivo plus low-dose Yervoy as first-line treatment for patients with advanced non-small cell lung cancer. [Bristol-Myers Squibb Company] Press Release

Merck’s KEYTRUDA^® Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

Merck announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration in China as monotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumors express PD-L1 as determined by a NMPA-approved test, with no EGFR or ALK genomic tumor aberrations. [Merck] Press Release

Mysterious Vaping Deaths: Why US Officials Are Focusing on Flavor

An outbreak of deadly lung injuries in vapers in the United States — many of them adolescents — shows no signs of stopping. So far, 805 e-cigarettes users have fallen ill, 12 of whom have died. The illnesses are fuelling a push among lawmakers and regulators to rein in the sale of e-cigarettes, in particular those with flavors that could be contributing to a worrying surge in youth vaping. [Nature News] Editorial

Split Decisions: How Brexit Has Taken a Toll on Five Researchers

On 23 June 2016, 34 million U.K. citizens took to the polls to vote on a simple, fateful question: Should the United Kingdom remain a part of the European Union, or should it leave? Nearly 52%—a majority of 1.3 million—wanted out, and conservative politicians vowed to carry out the people’s wishes. [ScienceInsider] Editorial

NEW AACR-KCA Joint Workshop on Precision Medicine
November 14-15, 2019
Seoul, Korea

Visit our events page to see a complete list of events in the community.

NEW Research Fellow – Lung Cancer (Dana-Farber Cancer Institute)

NEW Faculty Position – Pulmonary and Critical Care Medicine (Mayo Clinic Comprehensive Cancer Center)

Research Scientist – Fibrosis (Gilead Sciences, Inc.)

Scientific Officer – Lung and Skin Toxiciology (Federal Institute for Risk Assessment)

Postdoctoral Positions – Sepsis and Pulmonary Injury (University of Maryland)

Postdoctoral Position – Small Cell Lung Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Lung Inflammation (The Boston University Pulmonary Center)

Associate Director – Pulmonary Biology (Translate Bio, Inc.)

Postdoctoral Research Fellow – Lung Cancer (University Hospital of Cologne)

Postdoctoral Fellowship – Lung Epithelium (Boston University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.